Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal

seekingalpha05-20

Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.Zai Lab reported ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2436144649?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1203934257/image_1203934257.jpg","is_english":true,"pubTime":"2024-05-20 13:30","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2436144649","market":"fut","top_or_hot":-1,"title":"Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal","media":"seekingalpha","content":"<div>\n<p>Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.Zai Lab reported ...</p>\n\n<a href=\"https://seekingalpha.com/article/4694447-week-in-review-takeda-options-alzheimers-therapy-ac-immune\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeek In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-20 13:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4694447-week-in-review-takeda-options-alzheimers-therapy-ac-immune><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.Zai Lab reported ...</p>\n\n<a href=\"https://seekingalpha.com/article/4694447-week-in-review-takeda-options-alzheimers-therapy-ac-immune\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACIU","symbol_name":"AC Immune SA","start_time":0,"source_url":"https://seekingalpha.com/article/4694447-week-in-review-takeda-options-alzheimers-therapy-ac-immune","article_id":"2436144649","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1203934257/image_1203934257.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2436144649","pubTimestamp":1716183000,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.Zai Lab reported Ch","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACIU":"AC Immune SA","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4539":"次新股","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4532":"文艺复兴科技持仓","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4007":"制药","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0237698245.USD":"富达环球地产基金A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","SLGL":"Sol-Gel Technologies","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4559":"巴菲特持仓","BK4588":"碎股","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","5I4.SI":"ICP公司","BMY":"施贵宝","BK6512":"房地产股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK6004":"海运","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4581":"高盛持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4135":"资产管理与托管银行","ERAS":"Erasca, INC.","AC":"Associated Capital Group, Inc.","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"一周回顾：武田选择AC Immune的阿尔茨海默氏症治疗以22亿美元成交","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AC":1,"SLGL":1,"ERAS":1,"BMY":1,"ACIU":1,"5I4.SI":0.77},"content_text":"Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.Zai Lab reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.Beijing InnoCare Pharma has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy.   SolStock Deals and Financings Japan’s Takeda (TAK, OTCPK:TKPHF; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA (ACIU) of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments (see story). With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome. San Diego’s Erasca (ERAS) acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and temporarily discontinuing development on a third candidate. Erasca will also raise $160 million from investors. The company acquired ex-China rights to a pan-RAS molecular glue (ERAS-0015) from Joyo Pharmatech of Guangzhou in a $189 million deal and global rights to a pan-KRAS inhibitor (ERAS-4001) from Sichuan Medshine Discovery in a $170 million agreement. Shenzhen Beimei Pharma acquired greater China rights for Twyneo, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million. Sol-Gel will be eligible to receive up to $10 million in upfront and regulator milestones. The remaining $5 million is potential royalty payments. Twyneo is the only fixed-dose combination of tretinoin and benzoyl peroxide cream available in the US; it is approved to treat acne vulgaris in adults and pediatric patients. Beimei markets products for pediatrics patients with a portfolio of more than 40 drugs approved or in the pipeline. Trials and Approvals Shanghai’s Zai Lab (ZLAB; HK: 9688) reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) (see story). The approval is based on an open-label, single-arm, Phase I/II trial that evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC. In 2020, Zai Lab acquired China rights to the drug from Turning Point Therapeutics of San Diego for $25 million upfront and up to $151 million in milestones, plus royalties. Turning Point is now a division of Bristol-Myers Squibb (BMY). Shanghai Everest Medicines (HK: 1952) launched Nefecon, a treatment for IgA nephropathy (IgAN), in China by filling the first prescription. IgAN, a rare disease that accounts for 35-50% of glomerular disease cases in China, can cause end-stage renal disease that is treated by kidney replacement or dialysis. Nefecon is a targeted-release formulation of budesonide, a second-generation synthetic corticosteroid. In 2019, Everest acquired greater China rights to the drug from Calliditas Therapeutics (CALT, OTCPK:CLTEF) of Sweden in a $121 million agreement. Nefecon is already approved in the US and EU. Suzhou Ractigen Therapeutics reported that a China IND was approved for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis (ALS). RAG-17 is a therapeutic siRNA designed to suppress the SOD1 gene in ALS patients with pathogenic mutations. Of the more than 50 genes associated with ALS, SOD1 gene mutations account for approximately 20% of the cases. Using Ractigen's proprietary SCAD delivery platform, RAG-17 combines siRNA with an accessory oligonucleotide to improve efficacy in central nervous system tissues. In preclinical studies, RAG-17 showed the ability to improve motor function and prolong survival. Beijing InnoCare Pharma (OTCPK:INCPF; HK: 09969; SHA: 688428) has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy (see story). ICP-488 is a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor. The trial enrolled 129 patients who were randomized to one of three treatment groups in a 1:1:1 ratio: a 6mg once-daily group, a 9mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment. By binding the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines. Shanghai Mabwell (SHA: 688062) reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer. In 20 patients with advanced or metastatic disease, 50% reported an objective response and 80% experienced disease control. One patient had a complete response that has continued for 20 months so far. Mabwell says a China IND for the drug, 9MW2821, has also been accepted in combination with an immune checkpoint inhibitor. According to the company, 9MW2821 is the first the Nectin-4-targeting ADC developed by a Chinese company to start clinical trials. Nanjing IASO Bio announced that Science Immunology, a sub-journal of Science, published a single-cell analysis of its anti-BCMA CAR T cell therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disease that usually occurs in the optic nerve and spinal cord, though it can affect the brain. The disease, which occurs in flare-ups that can cause muscle weakness or blindness, is sometimes misdiagnosed as multiple myeloma. Last year, IASO and its partner, Innovent (OTCPK:IVBIY, OTCPK:IVBXF), were approved in China to launch Equecabtagene Autoleucel, an anti-BCMA CAR T drug, as a fourth-line therapy for multiple myeloma. Original Post  Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.1","shortVersion":"4.24.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436144649"}